The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …

Bladder cancer remains one of the most common and lethal diseases that cause
approximately 150,000 deaths per year worldwide. Over the past two decades, the options …

Urothelial carcinoma is a common malignancy that carries a poor prognosis when the
disease includes muscle invasion. Metastatic urothelial carcinoma is almost uniformly fatal …

Small-molecule kinase inhibitors are invaluable targeted therapeutics for the treatment of
various human diseases, especially cancers. While the majority of approved and developed …

Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment
of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is …

Abstract Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major
challenge. Comprehensive genomic profiling of tumors and identification of driver mutations …

We examined the anti-cancer effect of genistein, a soy-derived isoflavone, in human bladder
transitional cell carcinoma T24 cells. According to our data, genistein induced G2/M phase …

Bladder cancer (BCa) is the most common malignant disease of the urinary tract system, yet
the etiology is still poorly understood. Clinically, the majority of BCa patients progress to …

Cancers harbor significant genetic heterogeneity and patterns of relapse following many
therapies are due to evolved resistance to treatment. While efforts have been made to …